^
Association details:
| Biomarker: | EGFR T790M negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors
Published date:
08/08/2023
Excerpt:
Durvalumab and tremelimumab with chemotherapy demonstrated promising anti-tumor activity, particularly in EGFR T790M negative tumors. The safety profile was consistent with known AEs with chemoimmunotherapy in advanced lung cancer.
Secondary therapy:
Chemotherapy
